Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

nsitivity to Vidaza or mannitol and in patients with advanced malignant hepatic tumors.

In clinical studies, the most commonly occurring adverse reactions by SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse reactions by IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%) and hypokalemia (31.3%).

Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle. Because Vidaza is potentially hepatotoxic in patients with severe pre-existing hepatic impairment, caution is needed in patients with liver disease. In addition, Vidaza and its metabolites are substantially excreted by the kidneys and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Vidaza may cause fetal harm. While receiving treatment with Vidaza, women of childbearing potential should avoid becoming pregnant, and men should avoid fathering a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... COLUMBUS, Ohio, Jan. 8 IntelligentMDx a developer and ... that verification studies of the IntelligentMDx BK Viral ... the Limit of Detection, linearity, specificity and reproducibility ... were determined. The data obtain agreed with internally ...
... have identified mutations in a gene that predict a high ... Although the researchers caution that further research is needed to ... or IKAROS, lead to leukemia relapse, the findings ... to assess the risk of treatment failure. By using a ...
Cached Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6
(Date:12/19/2014)... 2014 (HealthDay News) -- Traveling through the same U.S. ... to three others within a four-hour time span, illustrating ... report shows. "The exposures in this report were ... an international terminal, highlighting the fact that measles is ... an infectious disease specialist at the U.S. Centers for ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 While countless companies ... do not realize the potential dangers of their purchase. Not ... prescription from a qualified doctor, but patients who buy hCG ... point that there is actually no real hCG present. Illegal ... where there are no safety standards and may contain unknown ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
(Date:12/17/2014)... WI (PRWEB) December 17, 2014 In ... Administrators and its Argus Claim Review division have ... of the most common ways savings are achieved on ... (TPA) attributes millions of dollars in savings to Argus ... in 2013. , As explained by Tom Doney, Cypress ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... Yosef Shiloh, Ph.D., a David and Inez Myers professor ... genetics and biochemistry in the Sackler School of Medicine ... Annual AACR G.H.A. Clowes Memorial Award for his studies ... genomic instability syndrome ataxia-telangiectasia (A-T). "Dr. Shiloh is ...
... that a novel form of personalized therapy that ... to fight tumors could treat metastatic melanoma and ... therapeutic approach against these and other cancers. ... body,s immune system to fight cancer. Immune cells, ...
... , MONDAY, Jan. 31 (HealthDay News) -- Two new studies ... cancer: melanoma, a deadly malignancy that first appears in the ... The first study, appearing in the Jan. 31 issue ... engineered immune cells from the patient to fight off the ...
... , MONDAY, Jan. 31 (HealthDay News) -- Daytime ... improves greatly after surgery for the disorder, according to a ... partially or completely blocked in short spurts, causing pauses in ... occur 30 times or more an hour, disrupting sleep. The ...
... stem cells in the gut relieves a potentially lethal complication ... published online on January 31 in the Journal of ... can cure diseases such as leukemia but it can also ... (GVHD). A group led by Takanori Teshima at Kyushu ...
... American Chemical Society (ACS) today launched the inaugural edition of ... online snapshot of the countless ways in which chemistry improves ... special video welcome from Nancy B. Jackson, Ph.D., who serves ... Sandia National Laboratories in New Mexico. Every month through ...
Cached Medicine News:Health News:Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award 2Health News:Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award 3Health News:Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma 2Health News:New Therapies Offer Insight Into Battling Deadly Melanomas 2Health News:New Therapies Offer Insight Into Battling Deadly Melanomas 3Health News:Drowsiness May Decline After Apnea Surgery 2Health News:American Chemical Society unveils International Year of Chemistry virtual journal 2Health News:American Chemical Society unveils International Year of Chemistry virtual journal 3
... VISION is Guidant's first cobalt chromium stent ... MINI VISION to have remarkably thin struts ... creating a highly deliverable stent. Less metal, ... outcomes in small vessel treatment. The Guidant ...
... IRIS Medical IQ 810 infrared diode ... retinal disorders and glaucoma. The Companys ... technological innovation and is designed to ... (MIP) procedures in the office and ...
... early is best corrected with GP lenses. ... be present, GP lenses will help the ... will neutralize the distortions of the corneal ... is a fitting challenge for even the ...
... "a quantum leap forward in the evolution of ... Rose K lens has become the world's most ... keratoconus.,Unlike traditional contact lenses, the complex geometry built ... the cone like shape of the cornea, for ...
Medicine Products: